Starpharma Holdings Limited's latest marketcap:
As of 07/16/2025, Starpharma Holdings Limited's market capitalization has reached $27.28 M. According to our data, Starpharma Holdings Limited is the 34227th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 27.28 M |
| Revenue (ttm) | 2.71 M |
| Net Income (ttm) | -8,170,005.2 |
| Shares Out | 418.22 M |
| EPS (ttm) | -0.02 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/22/2025 |
Starpharma Holdings Limited's yearly market capitalization.
| Date | Market Cap(A$) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/16/2025 | A$41.82 M | $27.28 M | -10.88% | 34227 |
| 12/31/2024 | A$45.99 M | $28.45 M | -34.3% | 31814 |
| 12/29/2023 | A$70.01 M | $47.66 M | -68.87% | 28085 |
| 12/30/2022 | A$224.87 M | $153.19 M | -58.74% | 19634 |
| 12/31/2021 | A$544.95 M | $395.35 M | -14.24% | 14794 |
| 12/31/2020 | A$635.41 M | $488.88 M | 40.98% | 11711 |
| 12/31/2019 | A$450.71 M | $316.17 M | 2.35% | 12460 |
| 12/31/2018 | A$440.37 M | $310.37 M | -12.61% | 11610 |
| 12/29/2017 | A$503.9 M | $393.46 M | 88.59% | 11573 |
| 12/30/2016 | A$267.19 M | $192.4 M | -2.25% | 12957 |
Company Profile
About Starpharma Holdings Limited
Starpharma Holdings Limited is a biopharmaceutical company specializing in the research, development, and commercialization of dendrimer-based products for pharmaceutical, life science, and other applications worldwide.
Key Products
- VivaGel BV – A non-antibiotic vaginal gel for treating bacterial vaginosis (BV) and preventing recurrent BV.
- VIRALEZE – An antiviral nasal spray.
- VivaGel Condom – An antiviral condom coating.
Dendrimer Enhanced Product (DEP) Platform
The company is advancing its DEP delivery platform, including:
- DEP SN38 – For ovarian and colorectal cancer (Phase II clinical trial).
- DEP cabazitaxel – For prostate and ovarian cancer (Phase II clinical trial).
- DEP docetaxel – For pancreatic and other cancers (Phase II clinical trial).
Additional Developments
- DEP HER2 radiodiagnostic & DEP HER2 ADC – For solid tumor treatment.
- SPL7013 – A vaginal gel under development.
Collaborations
Starpharma has partnered with Medicxi to develop Petalion Therapeutics, a novel cancer therapy leveraging its dendrimer technology.
Company Background
Founded in 1997, Starpharma Holdings Limited is headquartered in Abbotsford, Australia.
Frequently Asked Questions
-
What is Starpharma Holdings Limited's (ASX-SPL) current market cap?As of 07/16/2025, Starpharma Holdings Limited (including the parent company, if applicable) has an estimated market capitalization of $27.28 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Starpharma Holdings Limited (ASX-SPL) rank globally by market cap?Starpharma Holdings Limited global market capitalization ranking is approximately 34227 as of 07/16/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.